Shineco subsidiary to acquire 51% equity interest in InfiniClone

Shineco (SISI) announced that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong, entered into a Share Purchase Agreement with Dr. Lim Kah Meng to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim. InfiniClone is a biotechnology company focusing on the field of regenerative medicine. Its main business covers a variety of fields, from basic research to commercial applications, with a focus on induced pluripotent stem cell technology, regenerative medicine applications and the development of cosmeceuticals.